epocrates

Drug Updates: Week of February 23, 2026

March 2, 2026

Here's a quick roundup of last week’s new drug monographs and updates.

New Brand Monograph

Filkri (filgrastim-laha)

• Indications: 1) chemo-induced febrile neutropenia prophylaxis in adult and pediatric patients ≥7 months; 2) post-BMT neutropenia in adult and pediatric patients ≥7 months; 3) severe chronic neutropenia in adult and pediatric patients ≥7 months; and 4) various other
• Formulation: subcutaneous or intravenous injection

New and Expanded Indications

Darzalex Faspro (daratumumab/hyaluronidase-fihj)

• New: newly diagnosed multiple myeloma - combo w/ bortezomib, lenalidomide, dexamethasone, autologous HSCT ineligible adult patients
• Existing: newly diagnosed multiple myeloma - various
• Read more: Darzalex Faspro combo OK’d for newly diagnosed multiple myeloma

Formulation Updates

deferiprone

• Added new tablet strength: TAB: 1000 mg

Mounjaro (tirzepatide)

• Added injectable form: KwikPen pen in various concentrations

Ozempic (semaglutide)

• Added new tablet form: TAB: 1.5 mg, 4 mg, 9 mg

tacrolimus

• Added injectable form administered via IV infusion

Xpovio (selinexor)

• Added new pack: TAB (80 mg once weekly pack): 80 mg x4

Zepbound (tirzepatide)

• Added injectable forms: KwikPen pen and additional concentrations available in vial

First-time Generic

ciprofloxacin/hydrocortisone otic

• Indications: acute bacterial otitis externa in adult and pediatric patients ≥1 year
• Equivalent brand: Cipro HC

Investigational New Drugs (IND)

Garetosmab (garetosmab)

• Proposed indications: fibrodysplasia ossificans progressiva
• Status: pending FDA approval

Iberdomide (iberdomide)

• Proposed indications: relapsed or refractory multiple myeloma
• Status: pending FDA approval

Tirabrutinib (tirabrutinib)

• Proposed indications: relapsed or refractory multiple myeloma; primary CNS lymphoma
• Status: pending FDA approval